arrow_back Back Filing freshness 10-Q Q1 FY2025 SEC EDGAR

Cell Source, Inc.

CLCS
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
48 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Bullish
auto_awesome

Analytical Summary

Cell Source, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 3.9% ↗
FCF / Share $-0.01
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

48-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-1.48M
↓ -16.2% —
FCF / Share Free cash flow per share
$-0.01
↓ -210.6% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↓
88
Cash Quality →
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 12 years · 48 quarters